Novoteris has announced that Health Canada has okayed a planned Phase 2a clinical trial of the company’s Thiolanox inhaled nitric oxide gas for the treatment of non-tuberculous mycobacteria (NTM) lung infections. The study will enroll 10 patients excluded from an ongoing Phase 2 trial of Thiolanox in cystic fibrosis patients.
Novoteris President Alex Stenzler commented, “The clearances by Health Canada will enable us to expand our work with this novel therapy to a wider range of people with an exceptional need for more effective antimicrobials and represents another important opportunity for Novoteris.”
Read the Novoteris press release.
